Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Carvedilol

FDA-approved product (tablet, oral), marketed as Carvedilol, Coreg, Carvedilol Phosphate and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Carvedilol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Ventricular Dysfunction, Left

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha and beta blocking agents
FDA pharmacologic class
alpha-Adrenergic Blocker; beta-Adrenergic Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Carvedilol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Carvedilol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis

    NCT07587671 · start 2026-08-01

    Registered record
    Registry ID
    NCT07587671
    Conditions
    Liver Cirrhosis; Portal Hypertension; Gastroesophageal Varices Bleeding; Esophageal Varices; Hepatic Encephalopathy
    Interventions
    Underdilated VCX-TIPS; Endoscopic Variceal Ligation; Nonselective Beta-Blockers
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-07-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Portal Hypertension; Gastroesophageal Varices Bleeding; Esophageal Varices +1 more
    InterventionUnderdilated VCX-TIPS; Endoscopic Variceal Ligation; Nonselective Beta-Blockers
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis.

    NCT07465471 · start 2026-03-01

    Registered record
    Registry ID
    NCT07465471
    Conditions
    Liver Cirrhosis
    Interventions
    Carvedilol; Midodrine Oral Product
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2027-09-30
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis
    InterventionCarvedilol; Midodrine Oral Product
    PhaseNot applicable
    Registry statusNot yet recruiting

  • CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound

    NCT06861075 · start 2025-04-16

    Registered record
    Registry ID
    NCT06861075
    Conditions
    Cirrhosis; Portal Hypertension Related to Cirrhosis
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-16
    Completion
    2028-04-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis; Portal Hypertension Related to Cirrhosis
    InterventionCarvedilol
    PhaseNot applicable
    Registry statusRecruiting

  • Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction

    NCT06518694 · start 2025-02-11

    Registered record
    Registry ID
    NCT06518694
    Conditions
    Heart Failure
    Interventions
    Βeta-Blockers discontinued (with tapering)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-02-11
    Completion
    2027-10
    Enrolment
    1,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionΒeta-Blockers discontinued (with tapering)
    PhasePhase 3
    Registry statusRecruiting

  • Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients

    NCT07397481 · start 2024-03-01

    Registered record
    Registry ID
    NCT07397481
    Conditions
    Liver Cirrhosis; Arterial Hypertension
    Interventions
    Nebivolol 5 mg; Carvedilol 12.5 mg; Nebivolol 2.5 mg; Carvedilol 6.25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-03-01
    Completion
    2025-06-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Arterial Hypertension
    InterventionNebivolol 5 mg; Carvedilol 12.5 mg; Nebivolol 2.5 mg; Carvedilol 6.25 mg
    PhasePhase 4
    Registry statusCompleted

  • Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF

    NCT06078436 · start 2024-01

    Registered record
    Registry ID
    NCT06078436
    Conditions
    Heart Failure With Reduced Ejection Fraction; Cardiogenic Shock
    Interventions
    Pulmonary artery catheter
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-01
    Completion
    2028-03
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction; Cardiogenic Shock
    InterventionPulmonary artery catheter
    PhaseNot applicable
    Registry statusRecruiting

  • Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis

    NCT06122792 · start 2024-01

    Registered record
    Registry ID
    NCT06122792
    Conditions
    Portal Hypertension; Gastric Varices Bleeding; Portosystemic Shunt
    Interventions
    preemptive TIPS; standard second prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2024-01
    Completion
    2026-12
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPortal Hypertension; Gastric Varices Bleeding; Portosystemic Shunt
    Interventionpreemptive TIPS; standard second prophylaxis
    PhaseNot applicable
    Registry statusNot yet recruiting

  • The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension

    NCT06015373 · start 2023-06-01

    Registered record
    Registry ID
    NCT06015373
    Conditions
    Clinically Significant Portal Hypertension
    Interventions
    supress the night dose of carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-06-01
    Completion
    2023-07-31
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinically Significant Portal Hypertension
    Interventionsupress the night dose of carvedilol
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults

    NCT05893849 · start 2023-03-28

    Registered record
    Registry ID
    NCT05893849
    Conditions
    Aging
    Interventions
    Clinical probes
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-03-28
    Completion
    2024-04
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAging
    InterventionClinical probes
    PhaseNot recorded
    Registry statusUnknown

  • Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study.

    NCT05180292 · start 2022-01-07

    Registered record
    Registry ID
    NCT05180292
    Conditions
    Acute on Chronic Liver Failure
    Interventions
    Carvedilol 12.5 MG
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-01-07
    Completion
    2024-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute on Chronic Liver Failure
    InterventionCarvedilol 12.5 MG
    PhaseNot applicable
    Registry statusUnknown

  • Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

    NCT04757584 · start 2021-04-01

    Registered record
    Registry ID
    NCT04757584
    Conditions
    Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure; Heart Disease
    Interventions
    Beta blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-04-01
    Completion
    2023-04-28
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure +1 more
    InterventionBeta blockers
    PhasePhase 4
    Registry statusCompleted

  • Pharmacological Reduction of Right Ventricular Enlargement

    NCT04345796 · start 2021-02-15

    Registered record
    Registry ID
    NCT04345796
    Conditions
    Tricuspid Regurgitation; Right Ventricular Dilatation
    Interventions
    Carvedilol+Empagliflozin; Carvedilol; Empagliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-02-15
    Completion
    2024-06-03
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTricuspid Regurgitation; Right Ventricular Dilatation
    InterventionCarvedilol+Empagliflozin; Carvedilol; Empagliflozin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Ivabradine in Cirrhotic Cardiomyopathy

    NCT04111133 · start 2020-01-01

    Registered record
    Registry ID
    NCT04111133
    Conditions
    Cirrhotic Cardiomyopathy; Left Ventricular Dysfunction; Cirrhosis, Liver; Portal Hypertension
    Interventions
    Betablocker + ivabradine; Betablocker
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2024-12
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhotic Cardiomyopathy; Left Ventricular Dysfunction; Cirrhosis, Liver; Portal Hypertension
    InterventionBetablocker + ivabradine; Betablocker
    PhaseNot applicable
    Registry statusUnknown

  • Cardiac Changes in Early Parkinson's Disease: A Follow up Study

    NCT04218968 · start 2019-12-30

    Registered record
    Registry ID
    NCT04218968
    Conditions
    REM Sleep Behavior Disorder; Pre-motor Parkinson Disease; Symptomatic Parkinson Disease
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-12-30
    Completion
    2026-06-30
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionREM Sleep Behavior Disorder; Pre-motor Parkinson Disease; Symptomatic Parkinson Disease
    InterventionCarvedilol
    PhasePhase 2
    Registry statusActive not recruiting

  • Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

    NCT04023110 · start 2019-08-09

    Registered record
    Registry ID
    NCT04023110
    Conditions
    Cardiotoxicity; Risk Factor, Cardiovascular; Toxicity Due to Chemotherapy; Breast Cancer; Cardiomyopathies; Heart Failure
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-08-09
    Completion
    2025-01-14
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiotoxicity; Risk Factor, Cardiovascular; Toxicity Due to Chemotherapy; Breast Cancer +2 more
    InterventionCarvedilol
    PhasePhase 1
    Registry statusCompleted